Pfizer vs Verizon Communications: Which High-Yielding Dividend Stock Is the Better Buy?

Pfizer (PFE) yields ~7.1% and Verizon (VZ) yields ~6.7%, with both trading at <9x expected future earnings and long dividend histories. Verizon’s payout ratio is ~67% and it generated ~$20B free cash over the past four quarters versus ~$11.5B dividends, making the article conclude VZ is the safer buy; Pfizer’s payout ratio is >100% on reported earnings but is supported by cash flow, though dividend growth may slow as COVID-era tailwinds fade. The stock outlook hinges on Pfizer’s restructuring and healthcare exclusivity risks versus Verizon’s competitive uncertainty around Starlink/SpaceX.

Analysis

VZ is the cleaner cash-return story, but the market is likely underestimating how slowly competitive pressure can bleed through wireless: first in promo intensity, then in ARPU, then in free cash flow, with the equity multiple compressing well before dividend coverage breaks. That makes VZ less a growth compounder than a yield instrument whose downside is delayed but persistent if Starlink/fixed-wireless substitution forces price discipline across the sector.

PFE is the opposite setup: the dividend is not the real problem; the problem is that capital allocation is still being asked to do too many jobs at once. If restructuring only stabilizes cash flow rather than re-accelerating it, the stock can remain trapped in a low-multiple, low-confidence regime because every dollar returned to shareholders competes with pipeline repair and deal-making. The key question over 2-4 quarters is whether FCF consistently clears the dividend after normalization; if not, the market will keep treating the yield as a warning signal rather than a support.

Contrarian view: consensus may be too quick to call VZ "safe" and PFE "cheap." In a slow deterioration, VZ can actually be the more fragile equity because its valuation depends on the assumption that price competition stays rational; a small miss in wireless margin could re-rate the stock more than expected. By contrast, PFE’s issues are more visible and partially priced, so any credible FCF inflection or asset-sale discipline could create upside surprise, even if the near-term narrative remains poor.

Key Decisions for Investors

• Prefer VZ over PFE on a 3-6 month horizon for income exposure, but size modestly: the yield is supported today, yet the stock is vulnerable to a slow margin squeeze that could cap total return.
• Use PFE only as a watch item until trailing 12-month free cash flow covers the dividend by >1.1x for two consecutive quarters; if that does not happen, avoid fresh longs despite the headline yield.
• Relative-value trade: long VZ / short PFE for defensive-income exposure if you want to own the higher-quality balance sheet and cleaner payout support, with the hedge reducing idiosyncratic pharma execution risk.
• If VZ underperforms on Starlink-related headlines without a corresponding deterioration in reported service margin, consider adding on weakness; the market may be pricing near-term competition risk ahead of actual cash flow impact.
• Falsifier for the VZ thesis: a meaningful downgrade to wireless FCF guidance or sustained service-revenue/ARPU pressure over the next 1-2 earnings prints; if that occurs, the stock should be de-rated regardless of dividend yield.